BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology 2020;72:845-56. [PMID: 32190914 DOI: 10.1002/hep.31238] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 33.0] [Reference Citation Analysis]
Number Citing Articles
1 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Chen Y, Yang L, Millwood IY, Walters RG, Wang S, Chen J, Chen Z, Li L. Metabolic risk factors, genetic predisposition, and risk of severe liver disease in Chinese: a prospective study of 0.5 million people. Am J Clin Nutr 2021;114:496-504. [PMID: 33964851 DOI: 10.1093/ajcn/nqab099] [Reference Citation Analysis]
2 Bianco C, Tavaglione F, Romeo S, Valenti L. Genetic risk scores and personalization of care in fatty liver disease. Curr Opin Pharmacol 2021;61:6-11. [PMID: 34537584 DOI: 10.1016/j.coph.2021.08.014] [Reference Citation Analysis]
3 Wernberg CW, Ravnskjaer K, Lauridsen MM, Thiele M. The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients. J Clin Med 2021;10:930. [PMID: 33804302 DOI: 10.3390/jcm10050930] [Reference Citation Analysis]
4 Schnurr TM, Katz SF, Justesen JM, O'Sullivan JW, Saliba-Gustafsson P, Assimes TL, Carcamo-Orive I, Ahmed A, Ashley EA, Hansen T, Knowles JW. Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. Hepatol Commun 2022. [PMID: 35293152 DOI: 10.1002/hep4.1932] [Reference Citation Analysis]
5 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
6 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
7 Martin K, Hatab A, Athwal VS, Jokl E, Piper Hanley K. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. Curr Diab Rep 2021;21:8. [PMID: 33544287 DOI: 10.1007/s11892-021-01377-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? WJH 2022; 14(2):354-71. [DOI: 10.4254/wjh.v14.i2.354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sumida Y, Shima T, Mitsumoto Y, Katayama T, Umemura A, Yamaguchi K, Itoh Y, Yoneda M, Okanoue T. Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. Int J Mol Sci 2020;21:E4337. [PMID: 32570776 DOI: 10.3390/ijms21124337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
10 Pennisi G, Pipitone RM, Enea M, De Vincentis A, Battaglia S, Di Marco V, Di Martino V, Spatola F, Tavaglione F, Vespasiani-Gentilucci U, Zito R, Romeo S, Cammà C, Craxì A, Grimaudo S, Petta S. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. Hepatol Commun 2022. [PMID: 35146945 DOI: 10.1002/hep4.1877] [Reference Citation Analysis]
11 Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020;111S:154320. [PMID: 32712221 DOI: 10.1016/j.metabol.2020.154320] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
12 Gabriel-medina P, Ferrer-costa R, Rodriguez-frias F, Ciudin A, Augustin S, Rivera-esteban J, Pericàs JM, Selva DM. Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis. Biomedicines 2022;10:1015. [DOI: 10.3390/biomedicines10051015] [Reference Citation Analysis]
13 Pfeiffer RM, Rotman Y, O'Brien TR. Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score? Hepatology 2020;72:794-6. [PMID: 32506469 DOI: 10.1002/hep.31413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease–Related Genetic Variants. Clinical Gastroenterology and Hepatology 2020. [DOI: 10.1016/j.cgh.2020.12.033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
16 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Paternostro R, Staufer K, Traussnigg S, Stättermayer AF, Halilbasic E, Keritam O, Meyer EL, Stift J, Wrba F, Sipos B, Canbay A, Schlattjan M, Aigner E, Datz C, Stickel F, Schafmayer C, Hampe J, Buch S, Prager G, Munda P, Mandorfer M, Ferenci P, Trauner M. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatol Int 2021;15:922-33. [PMID: 34076851 DOI: 10.1007/s12072-021-10200-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet JM, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trépo E, Morgan TR, Seth D; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol 2021:S0168-8278(21)02111-5. [PMID: 34656649 DOI: 10.1016/j.jhep.2021.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Bai R, Rebelo A, Kleeff J, Sunami Y. Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis. Lipids Health Dis 2021;20:58. [PMID: 34078402 DOI: 10.1186/s12944-021-01476-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Zheng M, Allington G, Vilarinho S. Genomic medicine for liver disease. Hepatology 2022. [PMID: 35076957 DOI: 10.1002/hep.32364] [Reference Citation Analysis]
21 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-62. [PMID: 35569886 DOI: 10.1016/j.eprac.2022.03.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
23 Marchesini G, Taylor R. Genes and lifestyle: Which of the two is more relevant in driving NAFLD progression? Dig Liver Dis 2021;53:1433-4. [PMID: 34509395 DOI: 10.1016/j.dld.2021.08.011] [Reference Citation Analysis]
24 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
25 Hu C, Jia W. Multi-omics profiling: the way towards precision medicine in metabolic diseases. J Mol Cell Biol 2021:mjab051. [PMID: 34406397 DOI: 10.1093/jmcb/mjab051] [Reference Citation Analysis]
26 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
27 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Lahelma M, Luukkonen PK, Qadri S, Ahlholm N, Lallukka-Brück S, Porthan K, Juuti A, Sammalkorpi H, Penttilä AK, Arola J, Orho-Melander M, Yki-Järvinen H. Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. Nutrients 2021;13:E169. [PMID: 33429859 DOI: 10.3390/nu13010169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Vachher M, Bansal S, Kumar B, Yadav S, Arora T, Wali NM, Burman A. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. J Cell Biochem 2022. [PMID: 35818831 DOI: 10.1002/jcb.30252] [Reference Citation Analysis]
30 Xue W, Zhang L, Liu C, Gao Y, Li S, Huai Z, Dai J, Wang Y. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2032661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Dorairaj V, Sulaiman SA, Abu N, Abdul Murad NA. Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. Biomedicines 2021;10:15. [PMID: 35052690 DOI: 10.3390/biomedicines10010015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Dessein A. Clinical utility of polygenic risk scores for predicting NAFLD disorders. J Hepatol 2021;74:769-70. [PMID: 33653592 DOI: 10.1016/j.jhep.2021.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Jun DW. An analysis of polygenic risk scores for non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:446-7. [PMID: 34024056 DOI: 10.3350/cmh.2021.0133] [Reference Citation Analysis]
35 Nahon P, Allaire M, Nault JC, Paradis V. Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepat Oncol 2020;7:HEP36. [PMID: 33680428 DOI: 10.2217/hep-2020-0017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Wang J, Conti DV, Bogumil D, Sheng X, Noureddin M, Wilkens LR, Le Marchand L, Rosen HR, Haiman CA, Setiawan VW. Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort. Hepatol Commun 2021;5:1689-703. [PMID: 34558842 DOI: 10.1002/hep4.1751] [Reference Citation Analysis]
37 Zhang HB, Su W, Xu H, Zhang XY, Guan YF. HSD17B13: A Potential Therapeutic Target for NAFLD. Front Mol Biosci 2021;8:824776. [PMID: 35071330 DOI: 10.3389/fmolb.2021.824776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele L, Vespasiani-Gentilucci U, Anstee QM, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, Soardo G, Reeves H, Prati D, Romeo S, Valenti L. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol. 2021;74:775-782. [PMID: 33248170 DOI: 10.1016/j.jhep.2020.11.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
39 Patsenker E, Thangapandi VR, Knittelfelder O, Palladini A, Hefti M, Beil-Wagner J, Rogler G, Buch T, Shevchenko A, Hampe J, Stickel F. The Pnpla3 Variant I148M Reveals Protective Effects Towards Hepatocellular Carcinoma in Mice via Restoration of Omega-3 Polyunsaturated Fats. J Nutr Biochem 2022;:109081. [PMID: 35691594 DOI: 10.1016/j.jnutbio.2022.109081] [Reference Citation Analysis]
40 Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu Q, Dan YY, Schwartz M, Roberts LR, Yu ML, Nguyen MH. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. Hepatol Commun 2021;5:122-32. [PMID: 33437906 DOI: 10.1002/hep4.1606] [Reference Citation Analysis]
41 Meroni M, Longo M, Tria G, Dongiovanni P. Genetics Is of the Essence to Face NAFLD. Biomedicines 2021;9:1359. [PMID: 34680476 DOI: 10.3390/biomedicines9101359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology 2021;74:2241-50. [PMID: 34233030 DOI: 10.1002/hep.32047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
43 Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75:1476-84. [PMID: 34453963 DOI: 10.1016/j.jhep.2021.08.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
44 Åberg F, Luukkonen PK, But A, Salomaa V, Britton A, Petersen KM, Bojesen SE, Balling M, Nordestgaard BG, Puukka P, Männistö S, Lundqvist A, Perola M, Jula A, Färkkilä M. Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score. J Hepatol 2022:S0168-8278(22)00128-3. [PMID: 35271949 DOI: 10.1016/j.jhep.2022.02.021] [Reference Citation Analysis]
45 Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Männistö V, Sammalkorpi H, Penttilä AK, Hakkarainen A, Lehtimäki TE, Gaggini M, Gastaldelli A, Ala-Korpela M, Orho-Melander M, Arola J, Juuti A, Pihlajamäki J, Hodson L, Yki-Järvinen H. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)02150-4. [PMID: 34710482 DOI: 10.1016/j.jhep.2021.10.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
46 Seidelin AS, Nordestgaard BG, Tybjærg-Hansen A, Yaghootkar H, Stender S. A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population. Hepatol Int 2022. [PMID: 35397106 DOI: 10.1007/s12072-022-10331-w] [Reference Citation Analysis]
47 Innes H, Jepsen P, McDonald S, Dillon J, Hamill V, Yeung A, Benselin J, Went A, Fraser A, Bathgate A, Ansari MA, Barclay ST, Goldberg D, Hayes PC, Johnson P, Barnes E, Irving W, Hutchinson S, Guha IN. Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Rep 2021;3:100384. [PMID: 34805817 DOI: 10.1016/j.jhepr.2021.100384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Hudert CA, Adams LA, Alisi A, Anstee QM, Crudele A, Draijer LG, Furse S, Hengstler JG, Jenkins B, Karnebeek K, Kelly DA, Koot BG, Koulman A, Meierhofer D, Melton PE, Mori TA, Snowden SG, van Mourik I, Vreugdenhil A, Wiegand S, Mann JP; EU-PNAFLD investigators. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. Hepatol Commun 2022. [PMID: 35411667 DOI: 10.1002/hep4.1955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Li J, Chen H, Chen J, Zhou B, Hou J, Jiang DK. A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. Pharmgenomics Pers Med 2021;14:1505-15. [PMID: 34848996 DOI: 10.2147/PGPM.S337962] [Reference Citation Analysis]
50 Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med 2022;14:eabo4474. [PMID: 35731891 DOI: 10.1126/scitranslmed.abo4474] [Reference Citation Analysis]
51 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
52 Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Tur JA, Abete I, Zulet MA, Martinez JA. Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. Diagnostics (Basel) 2021;11:1083. [PMID: 34199237 DOI: 10.3390/diagnostics11061083] [Reference Citation Analysis]
53 Morgan MY, Sharma M, Atkinson SR. Genetic and Environmental Susceptibility to Alcoholic Hepatitis. Clin Liver Dis 2021;25:517-35. [PMID: 34229837 DOI: 10.1016/j.cld.2021.04.001] [Reference Citation Analysis]
54 De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00595-4. [PMID: 34091049 DOI: 10.1016/j.cgh.2021.05.056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
55 Nishida N. Metabolic disease as a risk of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:87-90. [PMID: 33317238 DOI: 10.3350/cmh.2020.0302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Liebe R, Keitel-anselmino V. Genetisches Risiko bei metabolischer Fettlebererkrankung: Gemeinsame Risikofaktoren für Fettlebererkrankung, Diabetes und Hyperlipidämie. Diabetologe 2020;16:552-9. [DOI: 10.1007/s11428-020-00647-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
58 Liu Z, Suo C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. Genetic predisposition, lifestyle risk, and obesity associate with the progression of nonalcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00379-0. [PMID: 34348882 DOI: 10.1016/j.dld.2021.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3:386-401. [PMID: 35484418 DOI: 10.1038/s43018-022-00357-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Schnabl B, Arteel GE, Stickel F, Hengstler J, Vartak N, Ghallab A, Dooley S, Li Y, Schwabe RF. Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. Z Gastroenterol 2022;60:36-44. [PMID: 35042252 DOI: 10.1055/a-1714-9330] [Reference Citation Analysis]
61 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]